Medicon Serum Amyloid A (SAA) is a CE marked reagent applied on Abbott Architect® Series (Cat. No. 1415-1250). A protocol for Beckman Coulter AU® Series analyzers is also available upon request.
Based on a latex enhanced immunoturbidimetric method, Medicon’s reagent is used for the in vitro quantitative measurement of the concentration of SAA in patients’ serum. SAA, an inflammation/infection marker has been proposed lately as a biomarker related to the severity and prognosis of Covid-19 infection. Increased concentration levels of SAA during the course of the disease correspond with poor prognosis1. Therefore, monitoring of SAA levels together with imaging techniques (CT) are helpful tools for the evaluation of the Covid-19 patient. Medicon provides also SAA calibrator (Cat. No 1478-1250) for the calibration of the serum application and controls (Cat. No. 1478-1255). Medicon SAA calibrator is traceable to WHO 1st International Standard 92/680.
1.Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis. Zinellua A, Paliogiannis P, Carrua C, Mangonid AA, Int J Infect Dis 2021; 105: 668-674.
